DLC1: a significant GAP in the cancer genome

Abstract
Rho GTPases are believed to make important contributions to the development and progression of human cancer, but direct evidence in the form of somatic mutations analogous to those affecting Ras has been lacking. A recent study inGenes & Developmentby Xue and colleagues (1439–1444)now provides in vivo evidence thatDLC1, a negative regulator of Rho, is a tumor suppressor gene deleted almost as frequently as p53 in common cancers such as breast, colon, and lung.